Optimizing antibody-dependent cellular phagocytosis for cancer immunotherapy: mechanisms, constraints, and therapeutic strategies. (PubMed, J Adv Res) - Oct 3, 2026 - "Accumulating evidence demonstrates that antibody-dependent cellular phagocytosis (ADCP), mediated by tumor-associated macrophages via Fcγ receptors (FcγR), represents a key Fc-dependent effector mechanism for selected antitumor monoclonal antibodies, including rituximab in B-cell malignancies, trastuzumab in HER2-positive cancers, cetuximab in EGFR-expressing tumors, and daratumumab in multiple myeloma. Third, it proposes that therapeutic ADCP should be defined by tumor selectivity and durable immune activation rather than engulfment alone. Fourth, it summarizes six major strategies to enhance beneficial ADCP, including Fc engineering, antigen-binding optimization, FcγRIIb blockade, targeting "don't-eat-me" signals, macrophage reprogramming, and combination with immune checkpoint inhibitors."
Journal • Review • Hematological Malignancies • Multiple Myeloma • Oncology • EGFR • HER-2
|
|
Hui Wang; Jiabin Xu; Lin Zhao; Miao Zhang; Mingyi Ju; Minjie Wei; Nan Li; Shiyu Xiao; Shuai Ma; Yilin Chen; Yufei An
|